Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis

2011; Elsevier BV; Volume: 44; Issue: 4 Linguagem: Inglês

10.1016/j.dld.2011.10.015

ISSN

1878-3562

Autores

Bram Blomme, Sven Francque, Eric Trépo, Louis Libbrecht, Dieter Vanderschaeghe, An Verrijken, Piet Pattyn, Yves Van Nieuwenhove, Dirk Van de Putte, Anja Geerts, Isabelle Colle, Joris R. Delanghe, Christophe Moreno, Luc Van Gaal, Nico Callewaert, Hans Van Vlierberghe,

Tópico(s)

Diet, Metabolism, and Disease

Resumo

Background Non-alcoholic fatty liver disease is a spectrum of disorders ranging from steatosis to non-alcoholic steatohepatitis (NASH). Steatosis of the liver is benign, whereas NASH can progress to cirrhosis or even hepatocellular carcinoma. Currently, a liver biopsy is the only validated method to distinct NASH from steatosis. Aim The objective of this study was to identify a biomarker specific for NASH based on the N-glycosylation of serum proteins. Methods N-glycosylation patterns were assessed using DNA sequencer-assisted fluorophore-assisted capillary electrophoresis and compared with histology. Results Initially, a glycomarker (log[NGA2F]/[NA2]) was developed based on the results obtained in 51 obese non-alcoholic patients scheduled for bariatric surgery. Multivariate analysis showed that our glycomarker had the lowest P-value of all biomarkers in distinguishing NASH from steatosis (P = 0.069). The glycomarker was validated in a cohort of 224 non-alcoholic fatty liver disease patients. In both pilot and validation study, glycomarker score increased in ascending amount of lobular inflammation (single-factor ANOVA, P ≤ 0.001 and P = 0.012, respectively). The N-glycan profile of immunoglobulin G in the NASH population confirmed the significantly increased undergalactosylation present in these patients. Conclusion Our glycomarker specifically recognises liver inflammation in obese individuals which is the main trigger for the development of steatohepatitis and can differentiate between steatosis and NASH.

Referência(s)